ERAS - Erasca, Inc.
Erasca Inc. (NASDAQ:ERAS) reported updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015, citing encouraging early activity in RAS-mutant solid tumors while outlining plans to advance the candidate into potentially registration-enabling studies.
New York, New York--(Newsfile Corp. - July 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline. SO WHAT: If you purchased Erasca common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
LOS ANGELES, July 14, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ:ERAS). IF YOU SUFFERED A LOSS ON YOUR ERASCA INVESTMENTS, CLICK HERE BEFORE AUGUST 10, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
New York, New York--(Newsfile Corp. - July 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Erasca securities between January 14, 2025 and April 26, 2026, both dates inclusive (the "Class Period").
NEW YORK, July 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Erasca, Inc. (NASDAQ: ERAS). Shareholders who purchased shares of ERAS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Important Information Regarding Section 20(a) Individual Liability Claims: Erasca's CEO and CFO Allegedly Certified Misleading Statements About ERAS-0015 While the Company Raised $258.8 Million From Investors Important Information Regarding Section 20(a) Individual Liability Claims: Erasca's CEO and CFO Allegedly Certified Misleading Statements About ERAS-0015 While the Company Raised $258.8 Million From Investors
Philadelphia, Pennsylvania--(Newsfile Corp. - July 14, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) ("Erasca" or the "Company") on behalf of investors who purchased or acquired Erasca common stock during the period from January 14, 2025 through April 26, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Erasca securities during the Class Period may, no later than August 10, 2026, seek to be appointed as a lead plaintiff representative of the class.
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 31,428,572 shares of its common stock. The shares of common stock are being sold to the public at a price of $17.50 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $550.0 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 4,714,285 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on July 15, 2026, subject to the satisfaction of customary closing conditions.
SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca's pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015. The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026.
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Erasca. In addition, Erasca intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock. There can be no assurance as to whether or when the proposed public offering may be completed, or as to the actual size or terms of the proposed offering.
At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100%
At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2LKRAS G12X pancreatic cancer in U. S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated at RDEs Promising combination potential, including no DLTs, encouraging safety data, and clearance of first dose escalation combination cohort of ERAS-0015 (16 mg) with approved commercial dose of panitumumab Additional ERAS-0015 monotherapy and combination data expected H1 2027, including panitumumab combination data Company plans to initiate a potentially registration-enabling trial in lung cancer in H1 2027, a Phase 3 trial in pancreatic cancer in 2027, and an additional Phase 3 trial in lung cancer in H2 2027 to H1 2028 SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc.
Key Dates and Disclosure Events Shareholders Need to Know: From J.P. Morgan Conference Claims to Patent Infringement Letter and Patient Death, a 15-Month Sequence of Events Cost ERAS Investors $11.59 Per Share Key Dates and Disclosure Events Shareholders Need to Know: From J.P. Morgan Conference Claims to Patent Infringement Letter and Patient Death, a 15-Month Sequence of Events Cost ERAS Investors $11.59 Per Share
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Erasca between January 14, 2025 and April 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 13, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the Erasca class action lawsuit. Captioned Cheng v.
LOS ANGELES, July 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Erasca, Inc. ("Erasca" or "the Company") (NASDAQ: ERAS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ERAS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
LOS ANGELES, July 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. ("Erasca" or "the Company") (NASDAQ: ERAS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 10, 2026.
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, July 12, 202
NEW YORK, July 12, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline. So what: If you purchased Erasca common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.